Desk›Healthcare› Venmax Drugs and Pharmaceuticals Ltd
Venmax Drugs and Pharmaceuticals Ltd
BSE 531015 · NSE VENMAX · ISIN INE154G01022 · Group X · Active
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
₹15.84
+8.72%
BSE close, 28 August 2026
₹18.35 cr
1.2 cr shares · Micro cap
₹15.57 cr
as published
66.0× · -19.56×
EPS ₹0.24 · BV ₹-0.81
8.03 / 0.25
₹ cr, as filed
14
4 selected · 29%
Reg 30
Sch. III Part A
Price 52-week, BSE
| Against 52-week high | -57.1% |
|---|---|
| Against 52-week low | +12.3% |
| Day change | +8.72% |
| Size band | Micro cap |
| Index membership | None |
Valuation as published by BSE
| Earnings per share | ₹0.24 |
|---|---|
| Price / earnings | 66.00× |
| Price / book | -19.56× |
| Book value — derived, price ÷ P/B | ₹-0.81 |
| Return on equity | -29.67% |
| Operating margin | 4.76% |
| Net margin | 4.72% |
Consistency check
- P/B ÷ P/E, which must equal ROE
- -29.64%
- ROE as published
- -29.67%
Results ₹ crore, as filed
RevenueNet profit one scale across all three periods, ₹ crore
| Period | Revenue ₹cr | Net profit ₹cr | EPS ₹ | OPM | NPM |
|---|---|---|---|---|---|
| Jun-26 · Q | 2.48 | 0.12 | 0.10 | 4.76% | 4.72% |
| Mar-26 · Q | 3.94 | 0.11 | 0.21 | 2.66% | 2.71% |
| FY25-26 | 8.03 | 0.25 | 0.21 | 3.50% | 3.09% |
Quarter on quarter
- Revenue, quarter on quarter
- -37.1%
- Net profit, quarter on quarter
- +9.1%
- Operating margin, quarter on quarter
- +210 bps
Disclosure profile 14 filings in the window
| Tag | Filings |
|---|---|
| Selected | |
| Board Outcome | 2 |
| Results | 1 |
| Scheme of Arrangement | 1 |
| Selected sub-total | 4 |
| Procedural | |
| Allotment | 2 |
| AGM / EGM | 1 |
| Annual Report | 1 |
| Board Meeting | 1 |
| Compliance Certificate | 1 |
| Court Convened Meeting | 1 |
| Newspaper Publication | 1 |
| Other Update | 1 |
| Trading Window | 1 |
| Procedural sub-total | 10 |
| Total | 14 |
Disclosure regime
LODR Reg 30
Read with Schedule III Part A. An equity filer in BSE Group X, so the Regulation 30 disclosure framework and the Schedule III event list both apply.
Filing rhythm · 93 trading days
14 filings · 4 selected · busiest 2026-08-07
Filing rhythm · the twelve most recent
2026-08-072026-10-08
SelectedProcedural
Filings
14 in the window · 1 earlier on record
-
8 October 2026 ·
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Regulation 74(5) of the SEBI(Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.
Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 View filing →
-
28 September 2026 ·
Shareholder Meeting / Postal Ballot-Scrutinizer's Report
Voting Results along with the Scrutinizers Report of the 37th Annual General Meeting of the Company held on 26th September 2026 through VC/OAVM.
AGM/EGM / AGM View filing →
-
25 September 2026 ·
Closure of Trading Window
Intimation of Closure of Trading Window pursuant to declaration of Unaudited Financial Results for the quarter ended September 30, 2026.
Insider Trading / SAST / Closure of Trading Window View filing →
-
24 September 2026 ·
Newspaper Publication
News paper Advertaisement of the meeting of Equity Share Holders Of Venmax Drugs and Pharmaceuticals Limited to be convened as per directions of Hon"ble National Company Law Tribunal ....
Company Update / Newspaper Publication View filing →
-
22 September 2026 ·
NCLT Conveying Shareholder Meeting On October 24, 2026 At 12.30 P.M.
Venmax Drugs and Pharmaceuticals Limited has informed exchange about the meeting of equity shareholders of the Company pursuant to the order passed by Hon. NCLT, Hyderabad bench II in respect ....
AGM/EGM / Court Convened Meeting View filing →
-
8 September 2026 ·
Scheme of Arrangement
Venmax Drugs and Pharmaceuticals Limited has informed the exchange about the update in respect of Scheme of Amalgamation of Hatri Pharma Private Limited (Amalgamating Company) with Venmax ....
Company Update / Scheme of Arrangement View filing →
-
1 September 2026 ·
Reg. 34 (1) Annual Report.
Submission of Annual Report for the Financial Year 2025-26 Pursuant to Regulation 34 and other relevant provisions of the SEBI (Listing Obligations & Disclosure Requirements), 2015.
Others / Reg. 34 (1) Annual Report View filing →
-
31 August 2026 ·
Board Meeting Outcome for Disclosure Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Pursuant to Regulation 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015, we would like to inform you that a meeting of Board of Directors of was held today i.e ....
Board Meeting / Outcome of Board Meeting View filing →
-
24 August 2026 ·
Board Meeting Intimation for Pursuant To Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Venmax Drugs And Pharmaceuticals Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/08/2026 ,inter alia, to consider and approve matters related ....
Board Meeting / Board Meeting View filing →
-
7 August 2026 ·
Statement Of Deviation & Variation
Statement of Deviation & Variation for the Quarter ended June 30, 2026.
Company Update / Reg. 32 (1), (3) - Statement of Deviation & Variation View filing →
-
7 August 2026 ·
Unaudited Financial Results For The Quarter Ended June 30, 2026.
Unaudited Financial Results along with Limited Review Report for the Quarter ended June 30, 2026.
Result / Financial Results View filing →
-
7 August 2026 ·
Board Meeting Outcome for Unaudited Financial Results For The Quarter Ended June 30, 2026.
Unaudited Standalone Financial Results along with the Limited Review Report For the Quarter ended June 30, 2026.
Board Meeting / Outcome of Board Meeting View filing →
-
30 July 2026 ·
Allotment
Allotment of 7,53,334 Convertible warrants in to Equity Shares on Preferential basis pursuant to Regulation 30 read with schedule III of SEBI LODR Regulation, 2015.
Company Update / Allotment of Equity Shares View filing →
-
29 July 2026 ·
Allotment
Allotment of 21,47,665 Convertible warrants in to Equity shares on preferential basis pursuant to Regulation 30 read with Schedule III of SEBI LODR Regulation, 2015.
Company Update / Allotment of Equity Shares View filing →
RSS feed for Venmax Drugs and Pharmaceuticals Ltd · the 50 most recent filings